menu
    • menu

    Company profile for Affinia Therapeutics

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At Affinia Therapeutics, our purpose is to develop gene therapies that can have a transformative impact on people affected by devastating genetic diseases. Our proprietary platform enables us to methodically engineer novel AAV vectors and gene therapies that have remarkable tissue targeting and other properties. We are building world-class capabilities to discover, develop, manufacture and commercialize gene therapy products w...
    At Affinia Therapeutics, our purpose is to develop gene therapies that can have a transformative impact on people affected by devastating genetic diseases. Our proprietary platform enables us to methodically engineer novel AAV vectors and gene therapies that have remarkable tissue targeting and other properties. We are building world-class capabilities to discover, develop, manufacture and commercialize gene therapy products with an initial focus on muscle and central nervous system (CNS) diseases with significant unmet need.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Affinia TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Waltham, Massachusetts 02451, US
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.affiniatx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Affinia Receives Approval from Canada to Initiate UPBEAT Trial
    Affinia Receives Approval from Canada to Initiate UPBEAT Trial

    06 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260406910176/en/Affinia-Therapeutics-Receives-Approval-from-Health-Canada-to-Initiate-the-UPBEAT-Trial-a-Phase-12-Clinical-Trial-to-Investigate-AFTX-201-as-a-Treatment-for-BAG3-Associated-Dilated-Cardiomyopathy-DCM

    BUSINESSWIRE
    06 Apr 2026
    Share Share
    Affinia Granted FDA Fast Track Designation for AFTX-201
    Affinia Granted FDA Fast Track Designation for AFTX-201

    04 Mar 2026

    // BUSSINESSWIRE

    https://www.businesswire.com/news/home/20260304031824/en/Affinia-Therapeutics-Granted-FDA-Fast-Track-Designation-for-AFTX-201-as-a-Treatment-for-People-Living-with-BAG3-Associated-Dilated-Cardiomyopathy-DCM

    BUSSINESSWIRE
    04 Mar 2026
    Share Share
    Affinia Pharma Granted EMA Orphan Drug Status For AFTX-201
    Affinia Pharma Granted EMA Orphan Drug Status For AFTX-201

    18 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260218739434/en/Affinia-Therapeutics-Receives-European-Medicines-Agency-Orphan-Drug-Designation-for-AFTX-201-in-BAG3-Associated-Dilated-Cardiomyopathy-DCM

    BUSINESSWIRE
    18 Feb 2026
    Share Share
    Affinia Therapeutics Advances AFTX-201 To Phase 1/2 Trial
    Affinia Therapeutics Advances AFTX-201 To Phase 1/2 Trial

    04 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260204711484/en/Affinia-Therapeutics-Announces-FDA-Acceptance-of-IND-Application-to-Advance-AFTX-201-to-a-Phase-12-Trial-for-the-Treatment-of-BAG3-Associated-Dilated-Cardiomyopathy-DCM

    BUSINESSWIRE
    04 Feb 2026
    Share Share
    Affinia Therapeutics Joins Investor Conferences
    Affinia Therapeutics Joins Investor Conferences

    14 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251014387033/en/Affinia-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences

    BUSINESSWIRE
    14 Oct 2025
    Share Share
    Affinia Therapeutics Announces Series C Financing
    Affinia Therapeutics Announces Series C Financing

    07 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251007974424/en/Affinia-Therapeutics-Announces-Series-C-Financing-to-Advance-New-Class-of-Gene-Therapies-Intended-to-Provide-Improved-Safety-and-Efficacy

    BUSINESSWIRE
    07 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search